In:
Cancer Science, Wiley, Vol. 106, No. 1 ( 2015-01), p. 102-107
Abstract:
Malignant pleural mesothelioma ( MPM ) is a rare and highly aggressive neoplasm that arises from the pleural, pericardial, or peritoneal lining. Although surgery, chemotherapy, radiotherapy, and combinations of these therapies are used to treat MPM , the median survival of such patients is dismal. Therefore, there is a compelling need to develop novel therapeutics with different modes of action. Ganglioside GM 2 is a glycolipid that has been shown to be overexpressed in various types of cancer. However, there are no published reports regarding the use of GM 2 as a potential therapeutic target in cases of MPM . In this study, we evaluated the efficacy of the anti‐ GM 2 antibody BIW ‐8962 as an anti‐ MPM therapeutic using in vitro and in vivo assays. Consequently, the GM 2 expression in the MPM cell lines was confirmed using flow cytometry. In addition, eight of 11 cell lines were GM 2‐positive (73%), although the GM 2 expression was variable. BIW ‐8962 showed a significant antibody‐dependent cellular cytotoxicity activity against the GM 2‐expressing MPM cell line MSTO ‐211H, the effect of which depended on the antibody concentration and effector/target ratio. In an in vivo orthotropic mouse model using MSTO ‐211H cells, BIW ‐8962 significantly decreased the incidence and size of tumors. Additionally, the GM 2 expression was confirmed in the MPM clinical specimens. Fifty‐eight percent of the MPM tumors were positive for GM 2, with individual variation in the intensity and frequency of staining. These data suggest that anti‐ GM 2 antibodies may become a therapeutic option for MPM patients.
Type of Medium:
Online Resource
ISSN:
1347-9032
,
1349-7006
DOI:
10.1111/cas.2015.106.issue-1
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
2115647-5
detail.hit.zdb_id:
2111204-6
Permalink